716 related articles for article (PubMed ID: 27836513)
1. Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Righini M; Galanaud JP; Guenneguez H; Brisot D; Diard A; Faisse P; Barrellier MT; Hamel-Desnos C; Jurus C; Pichot O; Martin M; Mazzolai L; Choquenet C; Accassat S; Robert-Ebadi H; Carrier M; Le Gal G; Mermilllod B; Laroche JP; Bounameaux H; Perrier A; Kahn SR; Quere I
Lancet Haematol; 2016 Dec; 3(12):e556-e562. PubMed ID: 27836513
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial.
Camporese G; Bernardi E; Prandoni P; Noventa F; Verlato F; Simioni P; Ntita K; Salmistraro G; Frangos C; Rossi F; Cordova R; Franz F; Zucchetta P; Kontothanassis D; Andreozzi GM;
Ann Intern Med; 2008 Jul; 149(2):73-82. PubMed ID: 18626046
[TBL] [Abstract][Full Text] [Related]
3. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial.
Kahn SR; Shapiro S; Wells PS; Rodger MA; Kovacs MJ; Anderson DR; Tagalakis V; Houweling AH; Ducruet T; Holcroft C; Johri M; Solymoss S; Miron MJ; Yeo E; Smith R; Schulman S; Kassis J; Kearon C; Chagnon I; Wong T; Demers C; Hanmiah R; Kaatz S; Selby R; Rathbun S; Desmarais S; Opatrny L; Ortel TL; Ginsberg JS;
Lancet; 2014 Mar; 383(9920):880-8. PubMed ID: 24315521
[TBL] [Abstract][Full Text] [Related]
4. Effect of anticoagulant treatment on pain in distal deep vein thrombosis: an ancillary analysis from the cactus trial.
Righini M; Robert-Ebadi H; Glauser F; Blondon M; Ouvry P; Diamand JM; Tissot A; Frappe P; Quere I; Kahn SR; Galanaud JP; Le Gal G
J Thromb Haemost; 2019 Mar; 17(3):507-510. PubMed ID: 30656824
[TBL] [Abstract][Full Text] [Related]
5. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations.
Bellosta R; Ferrari P; Luzzani L; Carugati C; Cossu L; Talarico M; Sarcina A
Angiology; 2007; 58(3):316-22. PubMed ID: 17626986
[TBL] [Abstract][Full Text] [Related]
6. Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study.
Schwarz T; Buschmann L; Beyer J; Halbritter K; Rastan A; Schellong S
J Vasc Surg; 2010 Nov; 52(5):1246-50. PubMed ID: 20630682
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
Nurmohamed MT; van Riel AM; Henkens CM; Koopman MM; Que GT; d'Azemar P; Büller HR; ten Cate JW; Hoek JA; van der Meer J; van der Heul C; Turpie AG; Haley S; Sicurella A; Gent M
Thromb Haemost; 1996 Feb; 75(2):233-8. PubMed ID: 8815566
[TBL] [Abstract][Full Text] [Related]
8. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
Beyer-Westendorf J; Schellong SM; Gerlach H; Rabe E; Weitz JI; Jersemann K; Sahin K; Bauersachs R;
Lancet Haematol; 2017 Mar; 4(3):e105-e113. PubMed ID: 28219692
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Anticoagulation for Isolated Calf Deep Vein Thrombosis.
Utter GH; Dhillon TS; Salcedo ES; Shouldice DJ; Reynolds CL; Humphries MD; White RH
JAMA Surg; 2016 Sep; 151(9):e161770. PubMed ID: 27437827
[TBL] [Abstract][Full Text] [Related]
10. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.
Prandoni P; Prins MH; Lensing AW; Ghirarduzzi A; Ageno W; Imberti D; Scannapieco G; Ambrosio GB; Pesavento R; Cuppini S; Quintavalla R; Agnelli G;
Ann Intern Med; 2009 May; 150(9):577-85. PubMed ID: 19414836
[TBL] [Abstract][Full Text] [Related]
11. 25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial.
Galanaud JP; Genty-Vermorel C; Barrellier MT; Becker F; Jabbour V; Blaise S; Bura-Rivière A; Comte A; Grange C; Guenneguez H; Maufus M; Ouvry P; Richaud C; Rolland C; Schmidt J; Sevestre MA; Verrière F; Bosson JL;
Lancet Haematol; 2022 Dec; 9(12):e886-e896. PubMed ID: 36455606
[TBL] [Abstract][Full Text] [Related]
12. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study.
Mahé I; Bergmann JF; d'Azémar P; Vaissie JJ; Caulin C
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):347-51. PubMed ID: 15981008
[TBL] [Abstract][Full Text] [Related]
13. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
Belcaro G; Nicolaides AN; Cesarone MR; Laurora G; De Sanctis MT; Incandela L; Barsotti A; Corsi M; Vasdekis S; Christopoulos D; Lennox A; Malouf M
Angiology; 1999 Oct; 50(10):781-7. PubMed ID: 10535716
[TBL] [Abstract][Full Text] [Related]
14. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
15. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
Agnelli G; Gussoni G; Bianchini C; Verso M; Mandalà M; Cavanna L; Barni S; Labianca R; Buzzi F; Scambia G; Passalacqua R; Ricci S; Gasparini G; Lorusso V; Bonizzoni E; Tonato M;
Lancet Oncol; 2009 Oct; 10(10):943-9. PubMed ID: 19726226
[TBL] [Abstract][Full Text] [Related]
16. Nadroparin or fondaparinux versus no thromboprophylaxis in patients immobilised in a below-knee plaster cast (PROTECT): A randomised controlled trial.
Bruntink MM; Groutars YME; Schipper IB; Breederveld RS; Tuinebreijer WE; Derksen RJ;
Injury; 2017 Apr; 48(4):936-940. PubMed ID: 28279428
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial.
Ageno W; Bertù L; Bucherini E; Camporese G; Dentali F; Iotti M; Lessiani G; Parisi R; Prandoni P; Sartori M; Visonà A; Bigagli E; Palareti G;
BMJ; 2022 Nov; 379():e072623. PubMed ID: 36520715
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
19. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France.
Fraisse F; Holzapfel L; Couland JM; Simonneau G; Bedock B; Feissel M; Herbecq P; Pordes R; Poussel JF; Roux L
Am J Respir Crit Care Med; 2000 Apr; 161(4 Pt 1):1109-14. PubMed ID: 10764298
[TBL] [Abstract][Full Text] [Related]
20. The controversy of managing calf vein thrombosis.
Masuda EM; Kistner RL; Musikasinthorn C; Liquido F; Geling O; He Q
J Vasc Surg; 2012 Feb; 55(2):550-61. PubMed ID: 22032881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
